The US Food and Drug Administration (FDA) has approved Agilent Resolution ctDx FIRST as a companion diagnostic (CDx) to identify advanced non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations who may benefit from treatment with KRAZATITM (adagrasib). Click to read more.
Agilent Technologies Inc. announced today that the U.S. Food and Drug Administration has approved Agilent Resolution ctDx FIRST as a companion diagnostic to identify advanced. | December 12, 2022
SANTA CLARA, Calif. (BUSINESS WIRE) Agilent Technologies Inc. (NYSE: A) announced today that the U.S. Food and Drug Administration (FDA) has approved Agilent Resolution ctDx FIRST as a companion diagnostic (CDx) to identify advanced non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations who may benef.
therascreenKRAS RGQ PCR kit approved as a companion diagnostic to aid in identifying non-small cell lung cancer (NSCLC) patients eligible for treatment with KRAZATI (adagrasib) KRAS mutations
Agilent Resolution ctDx FIRST Receives FDA Approval as a Liquid Biopsy Companion Diagnostic Test for Advanced Non-small Cell Lung Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.